drugset / Trial / NCT03859141
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy children aged 6-35 months.
Timeline
- Start
- 2018-02-06
- Primary completion
- 2018-04-17
- Completion
- 2018-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quadrivalent influenza vaccine | Vaccine | 7.5 ug | — |
| Subject | Quadrivalent influenza vaccine | Vaccine | 0.25 ml | — |
| Comparator | trivalent influenza vaccine (contains B/Victoria strain) | Vaccine | 7.5 ug | — |
| Comparator | trivalent influenza vaccine (contains B/Victoria strain) | Vaccine | 0.25 ml | — |
| Comparator | trivalent influenza vaccine (contains B/Yamagata strain) | Vaccine | 7.5 ug | — |
| Comparator | trivalent influenza vaccine (contains B/Yamagata strain) | Vaccine | 0.25 ml | — |